Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alzamend Neuro, Inc

3.19
-0.0134-0.42%
Volume:278.76K
Turnover:887.22K
Market Cap:2.55M
PE:-0.22
High:3.27
Open:3.21
Low:3.09
Close:3.20
Loading ...

Alzamend Neuro Inc. Eliminates Series A Preferred Stock in Bylaw Amendment

Reuters
·
10 Jul

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

THOMSON REUTERS
·
16 Jun

Press Release: Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Dow Jones
·
16 Jun

Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results

Benzinga
·
30 May

Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update

TIPRANKS
·
29 May

BRIEF-Alzamend Neuro Announces Dosing Of First Patient In Phase II Clinical Trial Of Al001 “Lithium In Brain” Study

Reuters
·
29 May

Alzamend Neuro Inc - Topline Data Expected by Year End

THOMSON REUTERS
·
29 May

Alzamend Neuro Announces Dosing of First Patient in Its Phase Ii Clinical Trial of Al001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

THOMSON REUTERS
·
29 May

BRIEF-Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study

Reuters
·
19 May

Alzamend Neuro Enrolls First Patient in Its Phase Ii Clinical Trial of Al001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

THOMSON REUTERS
·
19 May

Alzamend Neuro Inc - Topline Data for Al001 Expected by Year End

THOMSON REUTERS
·
19 May

Milton C. Ault III, Director and 10% Owner, Reports Disposal of Alzamend Neuro Inc. Common Shares

Reuters
·
15 May

Alzamend Neuro Initiates First Phase Ii Clinical Trial of Al001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

THOMSON REUTERS
·
13 May

Alzamend Neuro Inc - Reverse Split to Maintain Nasdaq Listing Compliance

THOMSON REUTERS
·
08 May

Alzamend Neuro Inc - Approves One-for-Nine Reverse Stock Split

THOMSON REUTERS
·
08 May

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?

Insider Monkey
·
28 Mar

Alzamend Neuro announces initiation date of Phase II trial of AL001

TIPRANKS
·
26 Mar

Alzamend Neuro Announces Initiation Date of Phase Ii Clinical Trial of Al001 for Treatment of Alzheimer’s Disease to Take Place at Massachusetts General Hospital

THOMSON REUTERS
·
25 Mar

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

GlobeNewswire
·
25 Mar

Alzamend Neuro Inc: Plans to Initiate Phase Ii Clinical Study of Al001 for Treatment of Patients With Mdd in Q4 of 2025

THOMSON REUTERS
·
18 Mar